Cargando…

Immunogenicity and safety of an intramuscular split-virion quadrivalent inactivated influenza vaccine in individuals aged ≥ 6 months in India

A quadrivalent split-virion inactivated influenza vaccine (IIV4; Fluzone® Quadrivalent, Sanofi Pasteur) has been available in the US since 2013 for individuals aged ≥ 6 months. Here, we describe the results of an open-label, multicenter trial (WHO Universal Trial Number U1111-1143–8370) evaluating t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Agarkhedkar, Sharad, Chhatwal, Jugesh, Kompithra, Rajeev Zachariah, Lalwani, Sanjay K., Narayan, Arun, Muninarayanaswam, Vinay, Gogtay, Nithya, Dotter, Kristin, Gresset-Bourgeois, Viviane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2019
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605869/ https://www.ncbi.nlm.nih.gov/pubmed/30762467 http://dx.doi.org/10.1080/21645515.2019.1565259

Ejemplares similares

Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial
por: Dubey, Anand Prakash, et al.
Publicado: (2015)

Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in pregnant women: a randomized, observer-blind trial
por: Vesikari, Timo, et al.
Publicado: (2019)

Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine
por: Montalban, Cecilia, et al.
Publicado: (2017)

Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18–60 years of age in the Republic of Korea
por: Choi, Won Suk, et al.
Publicado: (2017)

Enhanced passive safety surveillance of a quadrivalent inactivated split virion influenza vaccine in Finland during the influenza season 2020/21
por: Syrkina, Olga, et al.
Publicado: (2022)

Enhanced passive safety surveillance of the quadrivalent inactivated split-virion influenza vaccine (IIV4) in Finland during the 2019/20 influenza season
por: Chabanon, Anne-Laure, et al.
Publicado: (2021)

Eco-epidemiology triad to explain infectious diseases
por: John, T. Jacob, et al.
Publicado: (2023)

Enhanced passive safety surveillance of high‐dose and standard‐dose quadrivalent inactivated split‐virion influenza vaccines in Germany and Finland during the influenza season 2021/22
por: Gandhi‐Banga, Sonja, et al.
Publicado: (2022)

Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial
por: Sesay, Sanie, et al.
Publicado: (2017)

Safety and Immunogenicity of a Full-dose, Split-virion, Inactivated, Quadrivalent Influenza Vaccine in Healthy Children 6-35 Months of Age: A Randomized Controlled Clinical Trial
por: Robertson, Corwin A., et al.
Publicado: (2019)

Immunogenicity and safety of the quadrivalent inactivated split-virion influenza vaccine in populations aged ≥ 3 years: A phase 3, randomized, double-blind, non-inferiority clinical trial
por: Chen, Jianmin, et al.
Publicado: (2023)

Evaluation of determinants of the serological response to the quadrivalent split‐inactivated influenza vaccine
por: Wu, Shaohuan, et al.
Publicado: (2022)

Growth and sexual maturity pattern of girls with mental retardation
por: Baidwan, Sukhinder, et al.
Publicado: (2014)

Safety and Immunogenicity of an Egg-Cultivated Quadrivalent Inactivated Split-virion Influenza Vaccine (GC3110A) in Healthy Korean Children: a Randomized, Double-blinded, Active-controlled Phase III Study
por: Lee, Jin, et al.
Publicado: (2018)

Safety and immunogenicity of a quadrivalent, inactivated, split-virion influenza vaccine (IIV4-W) in healthy people aged 3-60 years: a phase III randomized clinical noninferiority trial
por: Huang, Xiaoyuan, et al.
Publicado: (2022)

Immunogenicity of Split Inactivated Quadrivalent Influenza Vaccine in Adults with Obesity in the 2017/2018 Season
por: Jagielska, Anna M., et al.
Publicado: (2021)

Immunogenicity and safety of 3-dose primary vaccination with combined DTPa-HBV-IPV/Hib in Indian infants
por: Lalwani, Sanjay K., et al.
Publicado: (2016)

A phase III randomized, open-label, non-inferiority clinical trial comparing liquid and lyophilized formulations of oral live attenuated human rotavirus vaccine (HRV) in Indian infants
por: Cohet, Catherine, et al.
Publicado: (2021)

Long-term follow-up in patients with HIV vaccinated with pandemic influenza A(H1N1)/09 AS03-adjuvanted split virion vaccine and seasonal trivalent influenza split virion vaccine
por: Pauksens, Karlis
Publicado: (2013)

The revised guidelines of the Medical Council of India for academic promotions: Need for a rethink
por: Aggarwal, Rakesh, et al.
Publicado: (2015)

The revised guidelines of the Medical Council of India for academic promotions: Need for a rethink
por: Aggarwal, Rakesh, et al.
Publicado: (2016)

The revised guidelines of the Medical Council of India for the academic promotions: Need for a rethink
por: Aggarwal, Rakesh, et al.
Publicado: (2016)

The revised guidelines of the Medical Council of India for academic promotions: Need for a rethink
por: Aggarwal, Rakesh, et al.
Publicado: (2016)

The revised guidelines of the Medical Council of India for academic promotions: Need for a rethink
por: Aggarwal, Rakesh, et al.
Publicado: (2016)

The revised guidelines of the Medical Council of India for academic promotions: Need for a rethink
por: Aggarwal, Rakesh, et al.
Publicado: (2016)

The revised guidelines of the Medical Council of India for academic promotions: Need for a rethink
por: Aggarwal, Rakesh, et al.
Publicado: (2016)

The revised guidelines of the Medical Council of India for academic promotions: Need for a rethink()
por: Aggarwal, Rakesh, et al.
Publicado: (2016)

The revised guidelines of the Medical Council of India for academic promotions: Need for a rethink()()
por: Aggarwal, Rakesh, et al.
Publicado: (2016)

The epidemiologic and economic impact of a quadrivalent human papillomavirus vaccine in Thailand
por: Termrungruanglert, Wichai, et al.
Publicado: (2021)

Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study
por: Pepin, Stephanie, et al.
Publicado: (2016)

LB14. Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Subjects Aged 65 Years and Older
por: Chang, Lee-Jah, et al.
Publicado: (2018)

Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants
por: Garland, Suzanne M., et al.
Publicado: (2022)

Safety and tolerability of a 2009 trivalent inactivated split‐virion influenza vaccine in infants, children and adolescents
por: Lambert, Stephen B., et al.
Publicado: (2013)

A Tale of COVID-19: Beyond Physical Ailment
por: Lohiya, Nirali, et al.
Publicado: (2020)

The rationale for quadrivalent influenza vaccines
por: Ambrose, Christopher S., et al.
Publicado: (2012)

Vaccination coverage and the factors influencing routine childhood vaccination uptake among communities experiencing disadvantage in Vellore, southern India: a mixed-methods study
por: Francis, Mark Rohit, et al.
Publicado: (2021)

An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2023)

Surveillance on the Immune Effectiveness of Quadrivalent andTrivalent Split Influenza Vaccines — Shenzhen Cityand Changzhou City, China, 2018–2019
por: Shu, Liumei, et al.
Publicado: (2020)

Intramuscular Lipoma of Tongue
por: Garg, Monika, et al.
Publicado: (2011)

531 Split-virion compared to Subunit Influenza Trivalent Influenza Vaccines Has Greater Effectiveness in Older Adults
por: Talbot, H. Keipp, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ki60m5h1atmevnvfk7lhjpdl1o